Skip to main content

Diseases Studied

The Rare Diseases Clinical Research Network is an NIH-funded research network of 21 active consortia or research groups working to advance treatment for diseases that are rare. Use the search tools on this page to find the diseases we currently study. You can reach out to the indicated consortia or research groups for more information on those diseases and studies underway.

This network focuses on clinical research and does not generally support clinical care outside of research activities. To learn about other rare diseases, please visit the Genetic and Rare Diseases Information Center (GARD), which is an NIH program that helps the public find reliable information about rare and genetic diseases. Their staff are specialists. Contact them at 1-888-205-2311 or email GARDinfo@nih.gov.

All Diseases > Spastic paraplegia 50

Spastic paraplegia 50

Alternative Names: SPG50

Disease Category: Spastic Paraplegia

Spastic paraplegia type 50 (SPG50) is a childhood-onset, complex form of hereditary spastic paraplegia caused by biallelic pathogenic variants in AP4M1, one of the four genes encoding the adaptor protein complex 4 (AP-4). Together with AP4B1 (SPG47), AP4E1 (SPG51), and AP4S1 (SPG52), it forms the group of AP-4–associated hereditary spastic paraplegias.

Research groups studying this disease

Spastic Paraplegia
SP-CERN logo

Spastic Paraplegia Centers of Excellence Research Network (SP-CERN)

Recruiting

The initial phase of the SP-CERN aims to establish the center of excellence sites and organize national and international collaboration. The network will establish research infrastructure, will harmonize research protocols with international partners, connect patients and families affected by HSP, and build collaborations with partners in the biotechnology and pharmaceutical industry. The central infrastructure includes a prospective, longitudinal natural history study, a comprehensive repository of biospecimen and cell lines, and a state-of-the art genomics platform.

CureSPG50 is working with the world top scientists, labs and hospitals to make a gene therapy for SPG50. With the incredible support of tens of thousands from around the world we have raised enough money to begin building this life changing treatment.